But Bourla has less empathy or understanding for what he said are the “small” number of people who have knowingly circulated misinformation. Those people can’t be qualified just bad people, he said, adding: “They are criminals. They have literally cost millions of lives.”
The interview was live-streamed online and the replay is available to watch here.
Pfizer and its German partner, BioNTech, on Tuesday asked the Food and Drug Administration to authorize a booster dose of its coronavirus vaccine for people 18 and older.
The FDA could clear the request by the end of the month, according to health officials who spoke on the condition of anonymity because they were not authorized to discuss the issue.
Despite Jackson repeatedly notifying Ventavia of the problems, the company reportedly took no corrective action. This prompted Jackson to send a complaint by email to the US Food and Drug Administration (FDA) – the country’s top regulatory body – in September 2020. But less than 24 hours later, Ventavia fired her in an apparent reprisal.
In a further surprise, the FDA did not follow up on Jackson’s complaint either.
In autumn 2020 Pfizer’s chairman and chief executive, Albert Bourla, released an open letter to the billions of people around the world who were investing their hopes in a safe and effective covid-19 vaccine to end the pandemic. “As I’ve said before, we are operating at the speed of science,” Bourla wrote, explaining to the public when they could expect a Pfizer vaccine to be authorised in the United States.1
But, for researchers who were testing Pfizer’s vaccine at several sites in Texas during that autumn, speed may have come at the cost of data integrity and patient safety. A regional director who was employed at the research organisation Ventavia Research Group has told The BMJ that the company falsified data, unblinded patients, employed inadequately trained vaccinators, and was slow to follow up on adverse events reported in Pfizer’s pivotal phase III trial. Staff who conducted quality control checks were overwhelmed by the volume of problems they were finding. After repeatedly notifying Ventavia of these problems, the regional director, Brook Jackson, emailed a complaint to the US Food and Drug Administration (FDA). Ventavia fired her later the same day.
(today)
The new numbers still show overwhelmingly strong protection against severe disease but diminished effectiveness against infection.
(16.04.2021)
„Ein wahrscheinliches Szenario ist, dass es die Notwendigkeit einer dritten Dosis geben wird, irgendwo zwischen sechs und zwölf Monaten, und danach eine jährliche Neu-Impfung, aber all das muss noch bestätigt werden“, sagte der Vorstandsvorsitzende des US-Pharmakonzerns dem US-Sender CNBC in einem am Donnerstag veröffentlichten, aber bereits Anfang April geführten Interview.
(23.04.2021)
As Bourla said in an interview with Channel 12 News last month, Bourla was impressed with Netanyahu’s “obsessiveness” with purchasing the vaccines. The Yisrael HaYom report added that Bourla was also impressed by Netanyahu’s insistence on having the lawyers from both sides joining in on the conversations in order to prevent any legal deterrents to the deal.
Ein nahezu perfekter Ort, um die Wirksamkeit eines neuen Impfstoffs unter „Real Life“-Bedingungen weiter zu erforschen. Oder, wie es Bourla im Februar bei NBC News sagte: „Israel wird gerade zum Labor für die Welt. Sie verwenden nur unseren Wirkstoff und haben bereits einen großen Teil ihrer Bevölkerung damit geimpft.“
Bourla und Bibi, so Netanyahus Spitzname, haben einen Datendeal geschmiedet.
Netanyahu‘s rivals, jealous over his ingenuity, won’t be able to take their eyes off him and will continue to respond with pointless stammering.
Bourla further noted that studies on the risk of the vaccine are also underway on pregnant women and younger children.
The CEO of Pfizer, the manufacturer of the main coronavirus vaccine used in Israel, has delayed his planned visit to Israel following warnings that Prime Minister Benjamin Netanyahu may exploit Albert Bourla‘s visit for his campaign ahead of Israel‘s March 23 election.
In an interview last week on NBC, Bourla said: “I believe Israel has become the world’s lab right now, because they are using only our vaccine … and they vaccinated a very big part of their population, so we can study both economy and health indices.”
Daniel Taylor, an expert in insider trading and an associate professor of accounting at the Wharton School of the University of Pennsylvania, has closely monitored stock trades by executives at companies developing coronavirus vaccines. He told NPR that the close timing between the adoption of Bourla‘s stock plan and the press release looked „very suspicious.“
„It‘s wholly inappropriate for executives at pharmaceutical companies to be implementing or modifying 10b5-1 plans the business day before they announce data or results from drug trials,“ Taylor said.